Pfizer's Covid-19 vaccine in the country "at this stage."The CDSCO's Subject Expert Committee (SEC) noted that "incidents of palsy, anaphylaxis and other SAE’s have been reported during post-marketing and the causality of the events with the vaccine is being investigated."The committee also stated that the firm "has not proposed any plan to generate safety and immunogenicity data in Indian population.""After detailed deliberation, the committee has not recommended for grant of permission for emergency use in the country at this stage," SEC further stated in its document.Earlier today, the US-based pharma company, which was the first drugmaker to seek emergency approval in India for its vaccine developed with Germany's BioNTech, made the.